Affymax Inc. reported unaudited financial results for the third quarter and nine months ended September 30, 2009. The net loss for the third quarter of 2009 was $18.4 million or $0.97 per share compared to a net loss of $26.2 million or $1.72 per share for the third quarter of 2008. The company recognized revenue for the quarter ended September 30, 2009 of $29.2 million compared to $21.6 million for the quarter ended September 30, 2008. The increase in revenue was the result of increased collaboration revenue from its partnership with Takeda Pharmaceutical Company Limited (Takeda), under their 2006 collaboration for development of Affymax's compound, Hematide(TM). Loss from operations was $18.7 million against $26.4 million a year ago. Net loss before benefit for income taxes was $18.4 million against $26.2 million a year ago. For the nine months, the company reported net loss of $62.2 million or $3.43 per share against $60.7 million or $4.00 per share a year ago. Total revenues were $81.9 million against $57.5 million a year ago. Loss from operations was $63.3 million against $62.2 million a year ago. Net loss before benefit for income taxes was $62.3 million against $60.7 million a year ago.

Affymax, Inc. expected to Report Fiscal Year 2009 Results on March 8, 2010. This event was calculated by Capital IQ (Created on November 4, 2009).

Affymax Inc. announced the appointment of Hollings C. Renton to the position of chairman of the company's board of directors effective December 1, 2009. Mr. Renton replaces Nick Galakatos who served as lead board member since the company's initial public offering in 2006 and who will be resigning his position as a member of the board of directors at the end of 2009. In addition to assuming the role of chairman of the board, Mr. Renton will also chair the company's Nominating and Governance Committee. Prior to joining Affymax's board in June 2009, Mr. Renton served as chairman of the board of Onyx Pharmaceuticals Inc. from 2000 to 2008, where he also served as president and chief executive officer from 1993 and as a director from 1992.